Semaglutide, Tirzepatide and Retatrutide: Receptors and Study Context

These three molecules are often grouped under the GLP-1 label. Their receptor profiles differ, and the evidence should be read at the level of the specific compound and study.

Receptor targets at a glance

What receptor terminology can tell you

The receptor profile helps identify the pathways a study is investigating. It does not specify the size of an outcome, the balance of benefits and adverse effects, or how a different formulation will behave. Those questions require the relevant experiment.

The retatrutide phase 2 paper studied adults with obesity and evaluated weight outcomes and safety within a defined protocol. It is a source for that investigation, not a direct comparison of every GLP-1-related molecule or commercial research preparation.

Build a comparison from matching questions

1. Write the endpoint you want to understand: receptor activity, exposure, weight change, a biomarker or another outcome.
2. Record each study's population, formulation, comparator and follow-up period.
3. Separate head-to-head comparisons from comparisons assembled across different trials.
4. Keep adverse findings and uncertainty alongside the reported outcome.

The study-comparison guide explains why headline percentages from separate trials should not become a league table.

Keep formulation and material identity visible

A matching compound name does not establish that a research vial is equivalent to the material used in a trial. Follow the retatrutide and tirzepatide dossiers for identity questions and source-led context. Read formulation-specific absorption evidence before transferring findings between routes.

Scope of this comparison

The papers above are selected study-reading examples, not an exhaustive current trial registry or an approval-status directory. Use the linked primary records and compound dossiers when a decision depends on a particular study, formulation or current status.